Cargando…

Repurposing Approved Drugs as Fluoroquinolone Potentiators to Overcome Efflux Pump Resistance in Staphylococcus aureus

Staphylococcus aureus is a versatile human commensal bacteria and pathogen that causes various community and hospital-acquired infections. The S. aureus efflux pump NorA which belongs to the major facilitator superfamily, confers resistance to a range of substrates. Many efflux pump inhibitors (EPIs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mahey, Nisha, Tambat, Rushikesh, Chandal, Nishtha, Verma, Dipesh Kumar, Thakur, Krishan Gopal, Nandanwar, Hemraj
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Microbiology 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8672906/ https://www.ncbi.nlm.nih.gov/pubmed/34908453 http://dx.doi.org/10.1128/Spectrum.00951-21

Ejemplares similares

Microbe-Derived Indole Metabolite Demonstrates Potent Multidrug Efflux Pump Inhibition in Staphylococcus aureus
por: Tambat, Rushikesh, et al.
Publicado: (2019)

Efflux pump inhibitory potential of indole derivatives as an arsenal against norA over-expressing Staphylococcus aureus
por: Chandal, Nishtha, et al.
Publicado: (2023)

Purification and biological activity of natural variants synthesized by tridecaptin M gene cluster and in vitro drug-kinetics of this antibiotic class
por: Jangra, Manoj, et al.
Publicado: (2019)

Alliance of Efflux Pumps with β-Lactamases in Multidrug-Resistant Klebsiella pneumoniae Isolates
por: Maurya, Navdezda, et al.
Publicado: (2019)

Tridecaptin M, a New Variant Discovered in Mud Bacterium, Shows Activity against Colistin- and Extremely Drug-Resistant Enterobacteriaceae
por: Jangra, Manoj, et al.
Publicado: (2019)

Potential Inhibitors of SARS-CoV-2 Main Protease (M(pro)) Identified from the Library of FDA-Approved Drugs Using Molecular Docking Studies
por: Verma, Dipesh Kumar, et al.
Publicado: (2022)

Spread of Efflux Pump Overexpressing-Mediated Fluoroquinolone Resistance and Multidrug Resistance in Pseudomonas aeruginosa by using an Efflux Pump Inhibitor
por: Adabi, Maryam, et al.
Publicado: (2015)

Pseudomonas koreensis Recovered From Raw Yak Milk Synthesizes a β-Carboline Derivative With Antimicrobial Properties
por: Kaur, Manpreet, et al.
Publicado: (2019)

Contribution of OqxAB Efflux Pump in Selection of Fluoroquinolone-Resistant Klebsiella pneumoniae
por: Szabo, Orsolya, et al.
Publicado: (2018)

Detection of Overexpression of Efflux Pump Expression in Fluoroquinolone-Resistant Pseudomonas aeruginosa Isolates
por: Al Rashed, Nouf, et al.
Publicado: (2020)

Repurposing Antidepressants and Phenothiazine Antipsychotics as Efflux Pump Inhibitors in Cancer and Infectious Diseases
por: Rácz, Bálint, et al.
Publicado: (2023)

Association of qnr Genes and OqxAB Efflux Pump in Fluoroquinolone-Resistant Klebsiella pneumoniae Strains
por: Amereh, Fereshteh, et al.
Publicado: (2023)

Alterations of gyrA, gyrB, and parC and Activity of Efflux Pump in Fluoroquinolone-resistant Acinetobacter baumannii
por: Park, Sunok, et al.
Publicado: (2011)

Ketone- and Cyano-Selenoesters to Overcome Efflux Pump, Quorum-Sensing, and Biofilm-Mediated Resistance
por: Szemerédi, Nikoletta, et al.
Publicado: (2020)

Tobramycin-Linked Efflux Pump Inhibitor Conjugates Synergize Fluoroquinolones, Rifampicin and Fosfomycin against Multidrug-Resistant Pseudomonas aeruginosa
por: Yang, Xuan, et al.
Publicado: (2018)

Role of the Two-Component System CiaRH in the Regulation of Efflux Pump SatAB and Its Correlation with Fluoroquinolone Susceptibility
por: Yang, Xia, et al.
Publicado: (2022)

Relationship of OqxAB efflux pump to antibiotic resistance, mainly fluoroquinolones in Klebsiella pneumoniae, isolated from hospitalized patients
por: Amereh, Fereshteh, et al.
Publicado: (2023)

Enhanced resistance to fluoroquinolones in laboratory-grown mutants & clinical isolates of Shigella due to synergism between efflux pump expression & mutations in quinolone resistance determining region
por: Taneja, Neelam, et al.
Publicado: (2015)

Promising FDA-approved drugs with efflux pump inhibitory activities against clinical isolates of Staphylococcus aureus
por: Abdel-Karim, Safaa Abdel-Aal Mohamed, et al.
Publicado: (2022)

Repurposing of approved cardiovascular drugs
por: Ishida, Junichi, et al.
Publicado: (2016)

Repurposing pantoprazole and haloperidol as efflux pump inhibitors in azole resistant clinical Candida albicans and non-albicans isolates
por: El-Ganiny, Amira M., et al.
Publicado: (2022)

Clinically Approved Drugs Inhibit the Staphylococcus aureus Multidrug NorA Efflux Pump and Reduce Biofilm Formation
por: Zimmermann, Saskia, et al.
Publicado: (2019)

Fluoroquinolone-derived fluorescent probes for studies of bacterial penetration and efflux
por: Stone, M. Rhia L., et al.
Publicado: (2019)

Giving Drugs a Second Chance: Overcoming Regulatory and Financial Hurdles in Repurposing Approved Drugs As Cancer Therapeutics
por: Hernandez, J. Javier, et al.
Publicado: (2017)

Repurposing approved drugs for cancer therapy
por: Schein, Catherine H
Publicado: (2021)

Overexpression of the Novel MATE Fluoroquinolone Efflux Pump FepA in Listeria monocytogenes Is Driven by Inactivation of Its Local Repressor FepR
por: Guérin, François, et al.
Publicado: (2014)

Discovery of bacteriorhodopsins in Haloarchaeal species isolated from Indian solar salterns: deciphering the role of the N‐terminal residues in protein folding and functional expression
por: Verma, Dipesh Kumar, et al.
Publicado: (2019)

Exploring the contribution of efflux on the resistance to fluoroquinolones in clinical isolates of Staphylococcus aureus
por: Costa, Sofia Santos, et al.
Publicado: (2011)

Role of bacterial efflux pumps in antibiotic resistance, virulence, and strategies to discover novel efflux pump inhibitors
por: Gaurav, Amit, et al.
Publicado: (2023)

Inhibition of Staphylococcus pseudintermedius Efflux Pumps by Using Staphylococcus aureus NorA Efflux Pump Inhibitors
por: Rampacci, Elisa, et al.
Publicado: (2023)

Effect of efflux pump inhibitors on the susceptibility of Mycobacterium tuberculosis to isoniazid
por: Jaiswal, Indu, et al.
Publicado: (2017)

Repurposing clinically approved cephalosporins for tuberculosis therapy
por: Ramón-García, Santiago, et al.
Publicado: (2016)

Repurposing approved drugs on the pathway to novel therapies
por: Schein, Catherine H.
Publicado: (2019)

In Vitro Evaluation of Antimicrobial Peptide Tridecaptin M in Combination with Other Antibiotics against Multidrug Resistant Acinetobacter baumannii
por: Jangra, Manoj, et al.
Publicado: (2020)

Biochemistry of Bacterial Multidrug Efflux Pumps
por: Kumar, Sanath, et al.
Publicado: (2012)

Efflux Pump-Mediated Resistance in Chemotherapy
por: Ughachukwu, PO, et al.
Publicado: (2012)

Efflux pump proteins in antifungal resistance
por: Prasad, Rajendra, et al.
Publicado: (2014)

Flavonoids as Inhibitors of Bacterial Efflux Pumps
por: Waditzer, Martin, et al.
Publicado: (2021)

Microbial Primer: Multidrug efflux pumps
por: Siasat, Pauline Ann, et al.
Publicado: (2023)

Overcoming anticancer resistance by photodynamic therapy-related efflux pump deactivation and ultrasound-mediated improved drug delivery efficiency
por: Kim, Doyeon, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_k8hvsnda27f8bhu0sl2pelejnu